NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Apollomics, Inc. (APLM) Stock Analysis

Apollomics, Inc. (APLM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

APLM

$27.50

−$0.52 (−1.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APLM with… →

APLM Key Statistics

As of Sep 4, 2026
Trading
Open
$27.50
Previous Close
$28.01
52-Week Range
5.20–42.12
Volume
1.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$79.63M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.01
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.43
Financials (FY)
Revenue (FY)
$8.50M
Net Income (FY)
−$10.94M
Profit marginThe share of revenue left as profit after all costs and taxes.
−123.72%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.90M
1-Year Return
+401.73%
Dividend and dates
Avg Volume
24.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APLM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+47.07%
2025+91.74%
2024−89.90%
2023−90.69%
2022+4.33%
2021 (partial year)+0.30%

As of September 4, 2026.

APLM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.50M−$10.94M−128.7%
2024$0.00−$53.86M—
2023$0.00−$172.60M—
2022$0.00−$240.81M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.50M—−$9.19M−$10.94M−128.7%
2024$0.00—−$42.03M−$53.86M—
2023$0.00—−$54.37M−$172.60M—
2022$0.00—−$44.39M−$240.81M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APLM Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPLMBiotechnology medianvs median
P/S ratio9.0115.2641% below
Profit margin−123.72%0.00%123.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Apollomics, Inc. (APLM) at $79.63M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 14.

APLM last closed at $27.50 on September 4, 2026. That is −$0.52 (−1.84%) against the previous close. Over the past 52 weeks the price has ranged from $5.20 to $42.12. The latest close sits 428.75% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $8.50M. The same year closed with a net loss of $10.94M. The reported profit margin is −123.72%. That is 123.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −7.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $8.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 9.01 times revenue. On price-to-sales that is 41% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.53. Annualized volatility over the trailing 4 years is 163.84%. The trailing one-year price return is +401.73%. Measured over 3 years, that is −60.76% a year compounded.

Growth & Income

The record shows no dividend for APLM.

Across the complete calendar years on file, 2025 returned +91.74% and 2023 returned −90.69%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the price is +47.07%.

Peer Comparison

Apollomics, Inc. (APLM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apollomics, Inc. APLM $79.63M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Apollomics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Apollomics, Inc.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

Visit website →